Arcturus Therapeutics Holdings Inc (ARCT) - Total Assets
Based on the latest financial reports, Arcturus Therapeutics Holdings Inc (ARCT) holds total assets worth $224.31 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arcturus Therapeutics Holdings Inc - Total Assets Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's total assets have evolved over time, based on quarterly financial data. Also see how much is Arcturus Therapeutics Holdings Inc worth for the company's overall valuation and market capitalisation.
Arcturus Therapeutics Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Arcturus Therapeutics Holdings Inc's total assets of $224.31 Million consist of 89.1% current assets and 11.0% non-current assets. Review Arcturus Therapeutics Holdings Inc (ARCT) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.2% |
| Accounts Receivable | $5.56 Million | 2.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ARCT share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arcturus Therapeutics Holdings Inc's current assets represent 89.1% of total assets in 2025, an increase from 55.4% in 2011.
- Cash Position: Cash and equivalents constituted 85.2% of total assets in 2025, up from 4.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 2.1% of total assets.
Arcturus Therapeutics Holdings Inc Competitors by Total Assets
Key competitors of Arcturus Therapeutics Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
USA | $1.21 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Arcturus Therapeutics Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.88 | 5.90 | 3.56 |
| Quick Ratio | 5.88 | 5.90 | 3.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $163.62 Million | $227.99 Million | $302.73 Million |
Arcturus Therapeutics Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Arcturus Therapeutics Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.44 |
| Latest Market Cap to Assets Ratio | 1.45 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | $271.15 Million |
| Market Capitalization | $393.66 Million USD |
Valuation Analysis
Above Book Valuation: The market values Arcturus Therapeutics Holdings Inc's assets above their book value (1.45x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Arcturus Therapeutics Holdings Inc's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arcturus Therapeutics Holdings Inc (2011–2025)
The table below shows the annual total assets of Arcturus Therapeutics Holdings Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $271.15 Million | -21.19% |
| 2024-12-31 | $344.07 Million | -19.87% |
| 2023-12-31 | $429.40 Million | -4.66% |
| 2022-12-31 | $450.39 Million | +14.66% |
| 2021-12-31 | $392.81 Million | -17.56% |
| 2020-12-31 | $476.46 Million | +480.03% |
| 2019-12-31 | $82.14 Million | +85.85% |
| 2018-12-31 | $44.20 Million | -15.04% |
| 2017-12-31 | $52.02 Million | +0.88% |
| 2016-12-31 | $51.57 Million | -28.06% |
| 2015-12-31 | $71.68 Million | +221.19% |
| 2014-12-31 | $22.32 Million | -55.65% |
| 2013-12-31 | $50.32 Million | +24936.82% |
| 2012-12-31 | $201.00K | -83.31% |
| 2011-12-31 | $1.20 Million | -- |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more